The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Open accessAbstract
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The authors flow-sorted the edited cells on the basis of the BCL11A-dependent switch to fetal haemoglobin, sequenced guides enriched in cells that had or hadn’t switched, and on the basis of those enrichments, successfully identified a primate-specific GATA1 motif critical for that enhancer’s function.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Cas9 introduces a targeted double-strand break, which is repaired by homology-directed repair using the donor templates, resulting in the incorporation of a single variant at the endogenous genomic locus (54, 55).”
From Massively parallel functional genomic assays in endocrinology: from promise to delivery (2026) · cites this paper as [54]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first such screen targeted gRNAs to effectively tile small indels across a known cluster of enhancers of BCL11A195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Canver et al 9 recently showed BCL11A enhancer disruption by CRISPR/Cas9 could induce fetal haemoglobin in both mice and primary human erythroblast cells.”
From What is CRISPR/Cas9? (2016) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The initial CRISPR screens of regulatory elements delivered an individual gRNA per cell195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
The cited source says what the claim attributes to it.
In the citing paper
“To date, all such screens use Cas9-induced perturbations, including active Cas9 for sequence disruption195, or nuclease dead-Cas9 (dCas9) tethered to an epigenetic repressor105 or activator domain92.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
In the citing paper
“In contrast, nine recently published CRISPR screens of noncoding sequences cumulatively studied regulatory effects on a total of 17 genes (Canver et al., 2015; Diao et al., 2016, 2017; Fulco et al., 2016; Gasperini et al., 2017; Klann et al., 2017; Korkmaz et al., 2016; Rajagopal et al., 2016; Sanjana et al., 2016).”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
In the citing paper
“First, they focus on the regulation of a single gene per experiment, typically entailing the development of a gene-specific assay.”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Self-citationGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHistone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Self-citation
Cited by
Sorted by citations
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Genome-wide association studies
Uffelmann, E., Huang, Q. Q., Munung, N. S., de Vries, J., Okada, Y., Martin, A. R., Martin, H. C., Lappalainen, T., & Posthuma, D. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00056-9 · Cited by 1,849
The next generation of CRISPR–Cas technologies and applications
Pickar-Oliver, A., & Gersbach, C. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0131-5 · Cited by 1,459
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Genome-scale CRISPR-Cas9 Knockout and Transcriptional Activation Screening
Joung, J., Konermann, S., Gootenberg, J. S., Abudayyeh, O. O., Platt, R. J., Brigham, M. D., Sanjana, N. E., & Zhang, F. (2017) · Nature Protocols · doi:10.1038/nprot.2017.016 · Cited by 1,243
Self-citationActivity-by-contact model of enhancer–promoter regulation from thousands of CRISPR perturbations
Fulco, C. P., Nasser, J., Jones, T. R., Munson, G., Bergman, D. T., Subramanian, V., Grossman, S. R., Anyoha, R., Doughty, B. R., Patwardhan, T. A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0538-0 · Cited by 1,111
Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
Walton, R. T., Christie, K. A., Whittaker, M. N., & Kleinstiver, B. P. (2020) · Science · doi:10.1126/science.aba8853 · Cited by 1,233
Long-range enhancer–promoter contacts in gene expression control
Schoenfelder, S., & Fraser, P. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0128-0 · Cited by 1,102
Richter, M. F., Zhao, K. T., Eton, E., Lapinaite, A., Newby, G. A., Thuronyi, B. W., Wilson, C., Koblan, L. W., Zeng, J., Bauer, D. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0453-z · Cited by 1,020
Self-citationThe epigenetic landscape of T cell exhaustion
Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986
Genome-editing Technologies for Gene and Cell Therapy
Maeder, M. L., & Gersbach, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.10 · Cited by 736
Determinants of enhancer and promoter activities of regulatory elements
Andersson, R., & Sandelin, A. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0173-8 · Cited by 713
A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens
Gasperini, M., Hill, A. J., McFaline-Figueroa, J. L., Martin, B., Kim, S., Zhang, M. D., Jackson, D., Leith, A., Schreiber, J., Noble, W. S., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.029 · Cited by 613
Systematic mapping of functional enhancer–promoter connections with CRISPR interference
Fulco, C. P., Munschauer, M., Anyoha, R., Munson, G., Grossman, S. R., Perez, E. M., Kane, M., Cleary, B., Lander, E. S., & Engreitz, J. M. (2016) · Science · doi:10.1126/science.aag2445 · Cited by 643
Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Topkar, V. V., Zheng, Z., & Joung, J. K. (2015) · Nature Biotechnology · doi:10.1038/nbt.3404 · Cited by 611
Past, present, and future of CRISPR genome editing technologies
Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609
Bock, C., Datlinger, P., Chardon, F. M., Coelho, M. A., Dong, M. B., Lawson, K. A., Lu, T., Maroc, L., Norman, T. M., Song, B., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00093-4 · Cited by 641
Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing
Leibowitz, M. L., Papathanasiou, S., Doerfler, P. A., Blaine, L. J., Sun, L., Yao, Y., Zhang, C.-Z., Weiss, M. J., & Pellman, D. (2021) · Nature Genetics · doi:10.1038/s41588-021-00838-7 · Cited by 583
Highly efficient therapeutic gene editing of human hematopoietic stem cells
Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., Clement, K., Cole, M. A., Luk, K., Baricordi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0401-y · Cited by 515
Self-citationInheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing
Amabile, A., Migliara, A., Capasso, P., Biffi, M., Cittaro, D., Naldini, L., & Lombardo, A. (2016) · Cell · doi:10.1016/j.cell.2016.09.006 · Cited by 516
DeWitt, M. A., Magis, W., Bray, N. L., Wang, T., Berman, J. R., Urbinati, F., Heo, S.-J., Mitros, T., Muñoz, D. P., Boffelli, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9336 · Cited by 477
Klann, T. S., Black, J. B., Chellappan, M., Safi, A., Song, L., Hilton, I. B., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3853 · Cited by 447
Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells
Hess, G. T., Frésard, L., Han, K., Lee, C. H., Li, A., Cimprich, K. A., Montgomery, S. B., & Bassik, M. C. (2016) · Nature Methods · doi:10.1038/nmeth.4038 · Cited by 474
Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch
Liu, N., Hargreaves, V. V., Zhu, Q., Kurland, J. V., Hong, J., Kim, W., Sher, F., Macias-Trevino, C., Rogers, J. M., Kurita, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.016 · Cited by 478
Self-citationAm I ready for CRISPR? A user's guide to genetic screens
Doench, J. G. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.97 · Cited by 452
DNA Repair Profiling Reveals Nonrandom Outcomes at Cas9-Mediated Breaks
van Overbeek, M., Capurso, D., Carter, M. M., Thompson, M. S., Frias, E., Russ, C., Reece-Hoyes, J. S., Nye, C., Gradia, S., Vidal, B., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.037 · Cited by 454
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
Esrick, E. B., Lehmann, L. E., Biffi, A., Achebe, M., Brendel, C., Ciuculescu, M. F., Daley, H., MacKinnon, B., Morris, E., Federico, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029392 · Cited by 449
CRISPR technologies for precise epigenome editing
Nakamura, M., Gao, Y., Dominguez, A. A., & Qi, L. S. (2021) · Nature Cell Biology · doi:10.1038/s41556-020-00620-7 · Cited by 456
Cornerstones of CRISPR–Cas in drug discovery and therapy
Fellmann, C., Gowen, B. G., Lin, P., Doudna, J. A., & Corn, J. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.238 · Cited by 452
Engineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H. S., Smith, D. M., & Omid Veiseh, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 472
CRISPR in cancer biology and therapy
Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00441-w · Cited by 457
Self-citationZhu, S., Li, W., Liu, J., Chen, C.-H., Liao, Q., Xu, P., Xu, H., Xiao, T., Cao, Z., Peng, J., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3715 · Cited by 427
Nucleosomes impede Cas9 access to DNA in vivo and in vitro
Horlbeck, M. A., Witkowsky, L. B., Guglielmi, B., Replogle, J. M., Gilbert, L. A., Villalta, J. E., Torigoe, S. E., Tjian, R., & Weissman, J. S. (2016) · eLife · doi:10.7554/elife.12677 · Cited by 429
Xu, Y., & Li, Z. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.031 · Cited by 457
Traxler, E. A., Yao, Y., Wang, Y.-D., Woodard, K. J., Kurita, R., Nakamura, Y., Hughes, J. R., Hardison, R. C., Blobel, G. A., Li, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4170 · Cited by 366
Self-citationFunctional genetic screens for enhancer elements in the human genome using CRISPR-Cas9
Korkmaz, G., Lopes, R., Ugalde, A. P., Nevedomskaya, E., Han, R., Myacheva, K., Zwart, W. T., Elkon, R., & Agami, R. (2016) · Nature Biotechnology · doi:10.1038/nbt.3450 · Cited by 405
Towards a comprehensive catalogue of validated and target-linked human enhancers
Gasperini, M., Tome, J. M., & Shendure, J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0209-0 · Cited by 396
Transcription factor–DNA binding: beyond binding site motifs
Inukai, S., Kock, K. H., & Bulyk, M. L. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.02.007 · Cited by 387
Genome-wide association studies of cancer: current insights and future perspectives
Sud, A., Kinnersley, B., & Houlston, R. S. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.82 · Cited by 391
Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin
Masuda, T., Wang, X., Maeda, M., Canver, M. C., Sher, F., Funnell, A. P. W., Fisher, C., Suciu, M., Martyn, G. E., Norton, L. J., et al. (2016) · Science · doi:10.1126/science.aad3312 · Cited by 373
Self-citationAn atlas of dynamic chromatin landscapes in mouse fetal development
Gorkin, D. U., Barozzi, I., Zhao, Y., Zhang, Y., Huang, H., Lee, A. Y., Li, B., Chiou, J., Wildberg, A., Ding, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2093-3 · Cited by 374
CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine
Kampmann, M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00657 · Cited by 387
Multiplexed Engineering and Analysis of Combinatorial Enhancer Activity in Single Cells
Xie, S., Duan, J., Li, B., Zhou, P., & Hon, G. C. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.03.007 · Cited by 334
A Two-Step Model for de Novo Activation of WUSCHEL during Plant Shoot Regeneration
Zhang, T., Lian, H., Zhou, C., Xu, L., Jiao, Y., & Wang, J. (2017) · The Plant Cell · doi:10.1105/tpc.16.00863 · Cited by 361
Tak, Y. G., & Farnham, P. (2015) · Epigenetics & Chromatin · doi:10.1186/s13072-015-0050-4 · Cited by 353
Epigenetic regulation of T cell exhaustion
Belk, J. A., Dániel, B., & Satpathy, A. T. (2022) · Nature Immunology · doi:10.1038/s41590-022-01224-z · Cited by 346
CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency
Matharu, N., Rattanasopha, S., Tamura, S., Maliskova, L., Wang, Y., Bernard, A., Hardin, A., Eckalbar, W. L., Vaisse, C., & Ahituv, N. (2019) · Science · doi:10.1126/science.aau0629 · Cited by 323
Kattamis, A., Kwiatkowski, J. L., & Aydınok, Y. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00536-0 · Cited by 337
CRISPR/Cas9-based engineering of the epigenome
Pulecio, J., Verma, N., Mejía-Ramírez, E., Huangfu, D., & Raya, A. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.09.006 · Cited by 300
Discovery of stimulation-responsive immune enhancers with CRISPR activation
Simeonov, D. R., Gowen, B. G., Boontanrart, M., Roth, T. L., Gagnon, J. D., Mumbach, M. R., Satpathy, A. T., Lee, Y., Bray, N. L., Chan, A. Y., et al. (2017) · Nature · doi:10.1038/nature23875 · Cited by 297
Maximizing mutagenesis with solubilized CRISPR-Cas9 ribonucleoprotein complexes.
Burger, A., Lindsay, H. A., Felker, A., Hess, C., Anders, C., Chiavacci, E., Zaugg, J., Weber, L. M., Catena, R., Jínek, M., et al. (2016) · Development · doi:10.1242/dev.134809 · Cited by 297
From profiles to function in epigenomics
Stricker, S. H., Köferle, A., & Beck, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.138 · Cited by 300
High-resolution interrogation of functional elements in the noncoding genome
Sanjana, N. E., Wright, J. B., Zheng, K., Shalem, O., Fontanillas, P., Joung, J., Cheng, C. S., Regev, A., & Zhang, F. (2016) · Science · doi:10.1126/science.aaf7613 · Cited by 290
Self-citationTherapeutic base editing of human hematopoietic stem cells
Zeng, J., Wu, Y., Ren, C., Bonanno, J., Shen, A. H., Shea, D. N., Gehrke, J. M., Clement, K., Luk, K., Yao, Q., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0790-y · Cited by 281
Self-citationNidhi, S., Anand, U., Olekšák, P., Tripathi, P., Lal, J. A., Thomas, G., Kuča, K., & Tripathi, V. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073327 · Cited by 310
Neugebauer, M. E., Hsu, A., Arbab, M., Krasnow, N. A., McElroy, A. N., Pandey, S., Doman, J. L., Huang, T. P., Raguram, A., Banskota, S., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01533-6 · Cited by 282
CRISPR technologies for genome, epigenome and transcriptome editing
Villiger, L., Joung, J., Koblan, L. W., Weissman, J. S., Abudayyeh, O. O., & Gootenberg, J. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00697-6 · Cited by 280
A tiling-deletion-based genetic screen for cis-regulatory element identification in mammalian cells
Diao, Y., Fang, R., Li, B., Meng, Z., Yu, J., Qiu, Y., Lin, K. C., Huang, H., Liu, T., Marina, R. J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4264 · Cited by 259
Gene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 263
GuideScan software for improved single and paired CRISPR guide RNA design
Perez, A. R., Pritykin, Y., Vidigal, J. A., Chhangawala, S., Zamparo, L., Leslie, C. S., & Ventura, A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3804 · Cited by 245
Refining strategies to translate genome editing to the clinic
Cornu, T. I., Mussolino, C., & Cathomen, T. (2017) · Nature Medicine · doi:10.1038/nm.4313 · Cited by 252
Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing
Li, K., Liu, Y., Cao, H., Zhang, Y., Gu, Z., Liu, X., Yu, A., Kaphle, P., Dickerson, K. E., Ni, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14362-5 · Cited by 257
Bock, C., Datlinger, P., Chardon, F. M., Coelho, M. A., Dong, M. B., Lawson, K. A., Lu, T., Maroc, L., Norman, T. M., Song, B., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00098-7 · Cited by 264
Redman, M., King, A., Watson, C., & King, D. (2016) · Archives of disease in childhood - Education & practice edition · doi:10.1136/archdischild-2016-310459 · Cited by 248
Huang, J., Liu, X., Li, D., Shao, Z., Cao, H., Zhang, Y., Trompouki, E., Bowman, T. V., Zon, L. I., Yuan, G., et al. (2016) · Developmental Cell · doi:10.1016/j.devcel.2015.12.014 · Cited by 247
Self-citationExagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309673 · Cited by 253
Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned
Morgan, R. A., Gray, D., Lomova, A., & Kohn, D. B. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.10.010 · Cited by 252
He, Q., Yu, D., Bao, M., Korensky, G., Chen, J., Shin, M., Kim, J., Park, M., Qin, P., & Du, K. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112068 · Cited by 240
A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing
Grünewald, J., Zhou, R., Lareau, C. A., Garcia, S. P., Iyer, S., Miller, B. R., Langner, L. M., Hsu, J. Y., Aryee, M. J., & Joung, J. K. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0535-y · Cited by 242
Self-citationDissecting super-enhancer hierarchy based on chromatin interactions
Huang, J., Li, K., Cai, W., Liu, X., Zhang, Y., Orkin, S. H., Xu, J., & Yuan, G.-C. (2018) · Nature Communications · doi:10.1038/s41467-018-03279-9 · Cited by 241
Self-citationEnhancer redundancy in development and disease
Kvon, E. Z., Waymack, R., Gad, M., & Wunderlich, Z. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00311-x · Cited by 247
Methods and Applications of CRISPR-Mediated Base Editing in Eukaryotic Genomes
Hess, G. T., Tycko, J., Yao, D., & Bassik, M. C. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.029 · Cited by 234
A New Class of Medicines through DNA Editing
Porteus, M. H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1800729 · Cited by 229
Lessons from Domestication: Targeting Cis-Regulatory Elements for Crop Improvement
Swinnen, G., Goossens, A., & Pauwels, L. (2016) · Trends in Plant Science · doi:10.1016/j.tplants.2016.01.014 · Cited by 224
Catarino, R. R., & Stark, A. (2018) · Genes & Development · doi:10.1101/gad.310367.117 · Cited by 215
Molecular basis of β thalassemia and potential therapeutic targets
Thein, S. L. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.06.001 · Cited by 219
Discovery of target genes and pathways at GWAS loci by pooled single-cell CRISPR screens
Morris, J. A., Caragine, C., Daniloski, Z., Domingo, J., Barry, T., Lu, L., Davis, K., Ziosi, M., Glinos, D. A., Hao, S., et al. (2023) · Science · doi:10.1126/science.adh7699 · Cited by 208
Self-citationGene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges
Cavazzana, M., Bushman, F. D., Miccio, A., André‐Schmutz, I., & Six, E. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0020-9 · Cited by 205
Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus
Antoniani, C., Meneghini, V., Lattanzi, A., Felix, T., Romano, O., Magrin, E., Weber, L., Pavani, G., El Hoss, S., Kurita, R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811505 · Cited by 194
Self-citationGenetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
Hoban, M. D., Orkin, S. H., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2015-09-618587 · Cited by 194
Self-citationGlobal marine microbial diversity and its potential in bioprospecting
Chen, J., Jia, Y., Sun, Y., Liu, K., Zhou, C., Liu, C., Li, D., Liu, G., Zhang, C., Yang, T., et al. (2024) · Nature · doi:10.1038/s41586-024-07891-2 · Cited by 205
Ye, L., Wang, J., Tan, Y., Beyer, A. I., Xie, F., Muench, M. O., & Kan, Y. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612075113 · Cited by 197
Genome editing of HBG1 and HBG2 to induce fetal hemoglobin
Métais, J.-Y., Doerfler, P. A., Mayuranathan, T., Bauer, D. E., Fowler, S. C., Hsieh, M. M., Katta, V., Keriwala, S., Lazzarotto, C. R., Luk, K., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000820 · Cited by 177
Self-citationDefining genome architecture at base-pair resolution
Peng, H., Badat, M., Hanssen, L. L. P., Hentges, L. D., Crump, N. T., Downes, D. J., Jeziorska, D. M., Oudelaar, A. M., Schweßinger, R., Taylor, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03639-4 · Cited by 189
Piel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O. E., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00096-0 · Cited by 203
Fu, B., Liao, J., Chen, S., Li, W., Wang, Q., Hu, J., Yang, F., Hsiao, S., Jiang, Y., Wang, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01906-z · Cited by 185
Development of CRISPR-Cas systems for genome editing and beyond
Zhang, F. (2019) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583519000052 · Cited by 188
Self-citationBak, R. O., Gomez‐Ospina, N., & Porteus, M. H. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.004 · Cited by 181
From variant to function in human disease genetics
Lappalainen, T., & MacArthur, D. G. (2021) · Science · doi:10.1126/science.abi8207 · Cited by 174
Lattanzi, A., Camarena, J., Lahiri, P., Segal, H., Srifa, W., Vakulskas, C. A., Frock, R. L., Kenrick, J., Lee, C. M., Talbott, N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf2444 · Cited by 171
Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
Brendel, C., Guda, S., Renella, R., Bauer, D. E., Canver, M. C., Kim, Y.-J., Heeney, M. M., Klatt, D., Fogel, J., Milsom, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87885 · Cited by 167
Self-citationGenome-scale high-resolution mapping of activating and repressive nucleotides in regulatory regions
Ernst, J., Melnikov, A., Zhang, X., Wang, L., Rogov, P., Mikkelsen, T. S., & Kellis, M. (2016) · Nature Biotechnology · doi:10.1038/nbt.3678 · Cited by 162
CRISPR-based functional genomics for neurological disease
Kampmann, M. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0373-z · Cited by 163
Gasperini, M., Findlay, G. M., McKenna, A., Milbank, J. H., Lee, C., Zhang, M. D., Cusanovich, D. A., & Shendure, J. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.06.010 · Cited by 143
The power of multiplexed functional analysis of genetic variants
Gasperini, M., Starita, L., & Shendure, J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.135 · Cited by 160
Quantifying the regulatory effect size of cis -acting genetic variation using allelic fold changePreprint
Mohammadi, P., Castel, S. E., Brown, A. A., & Lappalainen, T. (2017) · Genome Research · doi:10.1101/gr.216747.116 · Cited by 150
Chang, K.-H., Smith, S. E., Sullivan, T., Chen, K., Zhou, Q., West, J. A., Liu, M., Liu, Y., Vieira, B. F., Sun, C., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.009 · Cited by 155
Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells
Grevet, J. D., Lan, X., Hamagami, N., Edwards, C. R., Sankaranarayanan, L., Ji, X., Bhardwaj, S. K., Face, C. J., Posocco, D. F., Abdulmalik, O. Y., et al. (2018) · Science · doi:10.1126/science.aao0932 · Cited by 151
Dong, W., & Kantor, B. (2021) · Viruses · doi:10.3390/v13071288 · Cited by 162
Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements
Tycko, J., Wainberg, M., Marinov, G. K., Ursu, O., Hess, G. T., Ego, B. K., Aradhana, Li, A., Truong, A., Trevino, A. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11955-7 · Cited by 150
Metadata
- Authors
- Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., Luc, S., Kurita, R., Nakamura, Y., Fujiwara, Y., Maeda, T., Yuan, G.-C., Zhang, F., Orkin, S. H., & Bauer, D. E.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Broad Institute (US)
- RIKEN BioResource Research Center (JP)
- University of Tsukuba (JP)
- Brigham and Women's Hospital (US)
- Corresponding author
- Zhang, Feng
- Orkin, Stuart H.
- Bauer, Daniel E.
- ORCID
- Venue
- Nature
- Published
- 2015-09-16
- Volume
- 527
- Issue
- 7577
- Pages
- 192-197
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4644101
- OpenAlex
- W1855348513
- Cited by
- 886
- References
- 65
- Citations by year
- 2026: 43 · 2025: 72 · 2024: 76 · 2023: 79 · 2022: 68 · 2021: 91 · 2020: 85 · 2019: 92 · 2018: 87 · 2017: 94 · 2016: 89 · 2015: 8
- FWCI
- 51.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion)
- PMC
- Funders
- Howard Hughes Medical Institute
- U.S. Public Health Service (R01 A1084905)
- National Heart, Lung, and Blood Institute (P01HL032262, R01HL032259, R01HL119099)
- National Institute of Mental Health (DP1MH100706, R01MH110049)
- National Human Genome Research Institute (K99HG008171, R01HG005085, K99HG008399)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216, 5R01-DK097768, R01DK097768, F30DK103359, K08DK093705)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- BCL11A, enhancers, CRISPR/Cas9, fetal hemoglobin, sickle cell disease, beta-thalassemia, enhancer architecture, erythroblasts
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Animals, Base Sequence, Carrier Proteins, Cells, Cultured, DNA-Binding Proteins, Enhancer Elements, Genetic, Erythroblasts, Fetal Hemoglobin, Genetic Engineering, Humans, Molecular Sequence Data, Nuclear Proteins, Organ Specificity, Repressor Proteins, Species Specificity, Reproducibility of Results, Mutagenesis, Genome, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
